Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abbott Laboratories
(NY:
ABT
)
107.59
+0.52 (+0.49%)
Official Closing Price
Updated: 4:10 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abbott Laboratories
< Previous
1
2
3
4
5
Next >
Abbott Laboratories Outlook is Healthy: Buy the Dip
April 17, 2024
Abbott Laboratories had a steady quarter, producing growth, better-than-expected earnings, and raising the guidance. Analysts see the stock moving higher.
Via
MarketBeat
Exposures
COVID-19
Johnson & Johnson is as Cheap as it’s Going to Get
April 16, 2024
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely.
Via
MarketBeat
DexCom Stock Gains from GLP-1 Diabetic Users
April 02, 2024
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
Via
MarketBeat
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
March 20, 2024
Via
AB Newswire
Topics
Death
Exposures
Death
Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning
February 23, 2024
Via
Investor Brand Network
Abbott Laboratories (NYSE: ABT) Highlighted for Surprising Price Action
October 18, 2023
Via
Investor Brand Network
Medtronic is a Dividend Aristocrat That Keeps Gaining
March 11, 2024
A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector
Via
MarketBeat
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
Via
MarketBeat
4 med tech stocks with improving prognosis for 2024
January 31, 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025.
Via
MarketBeat
Exposures
COVID-19
Less Is More: Abbott’s Approach to Packaging Innovation
September 11, 2023
Via
ACCESSWIRE
Abbott Joins Billion Dollar Roundtable
September 07, 2023
Via
ACCESSWIRE
Abbott Laboratories on track for new highs in 2024
January 25, 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact.
Via
MarketBeat
Exposures
COVID-19
Johnson & Johnson's stock price is at a critical turning point
January 23, 2024
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Medtronic receives FDA approval for deep brain stimulation system
January 17, 2024
Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS)
Via
MarketBeat
Exposures
Product Safety
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
January 08, 2024
From
Tandem Diabetes Care, Inc.
Via
Business Wire
AbbVie continues shopping spree with biotech buyout
December 12, 2023
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.
Via
MarketBeat
Medtronic: oversold, overextended high yield reversal in play
November 22, 2023
The reversal in Medtronic has been brewing for some time but is gaining traction after strong second quarter earnings that came with improved guidance
Via
MarketBeat
Exposures
COVID-19
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
November 17, 2023
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
October 25, 2023
Dividend aristocrats Caterpillar, NextEra, and Clorox have shown resilience in challenging times. These may offer opportunities as they are trading off highs.
Via
MarketBeat
Exposures
COVID-19
The Value Deepens for Medtech Stocks: Reversal Imminent
October 23, 2023
MedTech stocks are performing well and supported by pent-up demand, yet share prices are trading at significant and often historical lows.
Via
MarketBeat
Oversold and Overextended, Abbott Laboratories is a Great Buy
October 18, 2023
Abbott Laboratories rises on solid results and guidance; the value and dividend are at the best levels in years, and the sell-side is buying.
Via
MarketBeat
Exposures
COVID-19
Lumentum Lights Up on the AI and ML Surge
October 10, 2023
Optical and photonics manufacturer Lumentum Holdings Inc. (NASDAQ: LITE) provides optical components and lasers to data centers, cloud providers, telecoms
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Stocks to Benefit from the Aging Population
September 26, 2023
The growth of the aging population is entirely predictable, which makes now an ideal time to consider these two health and wellness stocks
Via
MarketBeat
Topics
Retirement
Exposures
COVID-19
Pension
A Significant Reversal is in Sight for These 5 Med Tech Companies
August 30, 2023
Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand.
Via
MarketBeat
5 Good Reasons it's Time to Buy High-Yield Dividend King 3M
August 29, 2023
3M settled the ear plug lawsuit, clearing the path forward. The stock offers investors a high yield and value that may be too hard to pass up
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher
July 31, 2023
Strong Q2 earnings performance propelled DexCom higher. Investors cheered the glucose monitoring leader's bullish sales view and international expansion plans.
Via
MarketBeat
Johnson & Johnson's Inflection Point: What it Means for Investors
July 20, 2023
Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories.
Via
MarketBeat
Exposures
COVID-19
Abbott Laboratories Has the Prescription for Higher Share Prices
July 20, 2023
Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating.
Via
MarketBeat
Exposures
COVID-19
Agilent Technologies Stock: Ready to Rise off the Floor
June 21, 2023
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.
Via
MarketBeat
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
June 21, 2023
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next.
Via
MarketBeat
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.